Home » FDA Approves Third Wave s PGx Test for Camptosar Adverse Events

FDA Approves Third Wave s PGx Test for Camptosar Adverse Events

Aug 24, 2005

NEW YORK, Aug. 24 (GenomeWeb News) - Third Wave this week received approval from the US Food and Drug Administration for a pharmacogenetic test that takes advantage of the recent re-labeling of a lucrative chemotherapy drug.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.